David S.  Kabakoff net worth and biography

David Kabakoff Biography and Net Worth

Director of Castle Biosciences
David Kabakoff, Ph.D. has served as a member of our board of directors since September 2017. Since 2012, Dr. Kabakoff has served as a partner at HealthQuest Capital. Since 2007, Dr. Kabakoff has also served as an executive partner at Sofinnova Ventures. Dr. Kabakoff currently serves as chairman of the board of directors of NextCure, Inc., a publicly traded biopharmaceutical company. Dr. Kabakoff also serves on the board of directors of several private companies, including Antiva Biosciences, Inc., a biopharmaceutical company, Dauntless Pharmaceuticals, a biopharmaceutical company, Rarecyte, Inc., a life science tools company, Rainier Therapeutics, Inc., a biopharmaceutical company and Neurana Pharmaceuticals, Inc., a biopharmaceutical company. From 2006 until October 2014, Dr. Kabakoff served as a director of InterMune Inc., a publicly traded biopharmaceutical company. In 2001 Dr. Kabakoff co-founded Salmedix, Inc., a developer of cancer drug treatments, served as its Chairman and Chief Executive Officer and led its acquisition in June 2005 by Cephalon, Inc., a biopharmaceutical company. From 1996 to 2000, Dr. Kabakoff held the positions of Executive Vice President of Dura Pharmaceuticals, Inc. and President and Chief Executive Officer of Spiros, both pharmaceutical companies. From 1989 to 1996, Dr. Kabakoff was employed as Chief Executive Officer of Corvas International, Inc., a developer of biotherapeutics, and from 1983 to 1989 held senior executive positions with Hybritech, a biotechnology company. Dr. Kabakoff holds a B.A. degree in Chemistry from Case Western Reserve University and a Ph.D. from Yale University.

What is David S. Kabakoff's net worth?

The estimated net worth of David S. Kabakoff is at least $4.70 million as of June 22nd, 2020. Mr. Kabakoff owns 212,178 shares of Castle Biosciences stock worth more than $4,699,743 as of March 28th. This net worth evaluation does not reflect any other investments that Mr. Kabakoff may own. Learn More about David S. Kabakoff's net worth.

How do I contact David S. Kabakoff?

The corporate mailing address for Mr. Kabakoff and other Castle Biosciences executives is 820 S FRIENDSWOOD DRIVE SUITE 201, FRIENDSWOOD TX, 77546. Castle Biosciences can also be reached via phone at (866) 788-9007 and via email at [email protected]. Learn More on David S. Kabakoff's contact information.

Has David S. Kabakoff been buying or selling shares of Castle Biosciences?

David S. Kabakoff has not been actively trading shares of Castle Biosciences over the course of the past ninety days. Most recently, David S. Kabakoff sold 30,000 shares of the business's stock in a transaction on Thursday, June 17th. The shares were sold at an average price of $75.07, for a transaction totalling $2,252,100.00. Learn More on David S. Kabakoff's trading history.

Who are Castle Biosciences' active insiders?

Castle Biosciences' insider roster includes Daniel Bradbury (Director), Jeffrey Eberwein (CEO), Tobin Juvenal (Insider), David Kabakoff (Director), Derek Maetzold (Insider), Kristen Oelschlager (COO), Bernhard Spiess (Insider), Frank Stokes (CFO), and Adam Sussman (Director). Learn More on Castle Biosciences' active insiders.

Are insiders buying or selling shares of Castle Biosciences?

During the last year, Castle Biosciences insiders bought shares 1 times. They purchased a total of 4,800 shares worth more than $69,024.00. During the last year, insiders at the sold shares 40 times. They sold a total of 247,483 shares worth more than $5,133,815.82. The most recent insider tranaction occured on March, 20th when insider Derek J Maetzold sold 2,295 shares worth more than $46,519.65. Insiders at Castle Biosciences own 7.7% of the company. Learn More about insider trades at Castle Biosciences.

Information on this page was last updated on 3/20/2024.

David S. Kabakoff Insider Trading History at Castle Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/17/2021Sell30,000$75.07$2,252,100.00View SEC Filing Icon  
4/5/2021Sell70,000$72.20$5,054,000.00View SEC Filing Icon  
3/31/2021Sell30,000$67.76$2,032,800.00View SEC Filing Icon  
3/22/2021Sell10,000$67.12$671,200.00View SEC Filing Icon  
3/19/2021Sell10,000$66.17$661,700.00View SEC Filing Icon  
3/16/2021Sell120,000$63.74$7,648,800.00View SEC Filing Icon  
10/9/2020Sell50,000$54.20$2,710,000.00View SEC Filing Icon  
10/5/2020Sell25,000$52.09$1,302,250.00View SEC Filing Icon  
7/17/2020Sell25,000$43.04$1,076,000.00View SEC Filing Icon  
6/22/2020Sell175,000$40.50$7,087,500.00212,178View SEC Filing Icon  
2/19/2020Sell25,000$32.03$800,750.00View SEC Filing Icon  
2/13/2020Sell25,000$32.01$800,250.00View SEC Filing Icon  
7/29/2019Buy62,500$16.00$1,000,000.00View SEC Filing Icon  
See Full Table

David S. Kabakoff Buying and Selling Activity at Castle Biosciences

This chart shows David S Kabakoff's buying and selling at Castle Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Castle Biosciences Company Overview

Castle Biosciences logo
Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
Read More

Today's Range

Now: $22.15
Low: $21.33
High: $22.51

50 Day Range

MA: $22.05
Low: $18.06
High: $25.30

2 Week Range

Now: $22.15
Low: $9.26
High: $26.70

Volume

380,402 shs

Average Volume

259,251 shs

Market Capitalization

$608.02 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.9